Lipocine (NASDAQ:LPCN) will be announcing its earnings results on Monday, March 5th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Lipocine (NASDAQ LPCN) opened at $1.70 on Friday. The company has a market capitalization of $36.03, a P/E ratio of -1.77 and a beta of -0.94. Lipocine has a 52-week low of $1.15 and a 52-week high of $5.33.

A number of research analysts have commented on LPCN shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Lipocine in a research report on Friday, December 8th. Canaccord Genuity downgraded Lipocine from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $11.00 target price on shares of Lipocine in a report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Lipocine currently has an average rating of “Hold” and an average price target of $13.50.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with's FREE daily email newsletter.